Charles river and the francis crick institute combine expertise in antibody-drug conjugate development

Wilmington, mass.--(business wire)---- $crl #cdmo--charles river laboratories international, inc. (nyse: crl) and the francis crick institute (crick) today announced a new collaboration around antibody-drug conjugate (adc) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies. this agreement leverages an integrated approach to streamline discovery and characterization—bringing promising adc candidates to the clinic faster.
CRL Ratings Summary
CRL Quant Ranking